Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Obesity and Nonalcoholic Fatty Liver Disease
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT00262964
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
- Conditions
- Cardiovascular DiseasesHeart DiseasesHIV InfectionsHyperlipidemiaHypertriglyceridemiaInsulin ResistanceAtherosclerosis
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 221
- Registration Number
- NCT00246376
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
The Low HDL On Six Weeks Statin Therapy (LOW) Study
- Conditions
- LipoproteinsHDL CholesterolCoronary Arteriosclerosis
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Craigavon Area Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00238004
- Locations
- 🇬🇧
Craigavon Cardiac Centre, Craigavon, United Kingdom
Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
- Conditions
- Atherosclerosis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-01-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70
- Registration Number
- NCT00232531
- Locations
- 🇬🇧
Oxford University, Oxford, United Kingdom
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
- Conditions
- HypercholesterolemiaHyperlipidemia
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-08-12
- Target Recruit Count
- 30
- Registration Number
- NCT00203476
- Locations
- 🇺🇸
Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, Alabama, United States
Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression
- Conditions
- Healthy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-03-15
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 18
- Registration Number
- NCT00176020
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
- Conditions
- AtherosclerosisCardiovascular Disease
- Interventions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 145
- Registration Number
- NCT00127218
- Locations
- 🇺🇸
Johns Hopkins Unversity School of Medicine, Baltimore, Maryland, United States
Niacin Plus Statin to Prevent Vascular Events
- Conditions
- Cerebrovascular AccidentCoronary DiseaseCardiovascular DiseasesAtherosclerosisHeart DiseasesMyocardial Infarction
- Interventions
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Axio Research. LLC
- Target Recruit Count
- 3414
- Registration Number
- NCT00120289
- Locations
- 🇺🇸
Clinical Research Consultants, Inc., Hoover, Alabama, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸Iowa Heart Center, P.C., Des Moines, Iowa, United States
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 575
- Registration Number
- NCT00111891
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
- Conditions
- Diabetes Mellitus, Type 2HyperlipidemiaKidney Failure, Chronic
- Interventions
- Other: Placebo
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 9
- Registration Number
- NCT00108485
- Locations
- 🇺🇸
Univesity of Miami/Diabetes Research Institute, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.